Improvement of Chronic Hepatic Encephalopathy in Dogs by the Benzodiazepine-Receptor Partial Inverse Agonist Sarmazenil, but Not by the Antagonist Flumazenil
- 145 Downloads
Therapeutic modulation of the increased GABAergic tone in chronic hepatic encephalopathy (HE) by the benzodiazepine receptor (BR) antagonist flumazenil (F) has led to conflicting results in humans and animal models for HE. The BR inverse agonist sarmazenil (S) has only been used in animal models of acute HE. Therefore we investigated the effects of intravenous injection of F and S in dogs with chronic HE 8 to 12 weeks after placement of a portocaval shunt and 40% hepatectomy (n=7), compared to sham-operated pair-fed controls (n=7). The HE dogs had hyperammonemia (298±48 μM v 33±3 before surgery (mean±SEM)) and signs of HE at the start of the experiments (0.9±0.1 (scale 0-4)). Three (S3) and 8 (S8) mg/kg of S resulted in a significant improvement of encephalopathy (grade 0.9±0.2 immediately before v 0.5±0.1 after injection (S3) and 0.7±0.1 v 0.3±0.1 (S8)) and increase in mean dominant frequency of the EEC (MDF; 9.1±0.7 Hz v 11.1±0.3 (S3) and 8.9±0.5 v 11.0±0.3 (S8)) in HE dogs, whereas 15 mg/kg of S, 3 and 8 mg/kg of F, and the vehicle had no significant effects. The efficacy of S in these dogs is consistent with an increased GABAergic tone in the pathogenesis of chronic HE. The lack of effects of F makes a role for endogenous benzodiazepines herein unlikely.
Unable to display preview. Download preview PDF.
- Bansky G., Meier P.J., Ziegler W.H., Walser H., Schmid M., and Huber M. (1985). Reversal of hepatic coma by benzodiazepine antagonist Ro15-1788. Lancet i:1324–1325.Google Scholar
- Basile A.S., Hughes R.D., Harrison P.M., Murata Y., Pannell L., Jones E.A. et al. (1991a). Elevated brain concentrations of 1,4-benzodiazepines in fulminant hepatic failure. N. Engl. J. Med. 325:473–478.Google Scholar
- Butterworth R.F., Lavoie J., Giguere J.F., and Pomier-Layrargues G. (1988). Affinities and densities of high-affinity 3H-muscimol (GABA-A) binding sites and of central benzodiazepine receptors are unchanged in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy. Hepatology 8:1084–1088.PubMedGoogle Scholar
- Conn H.O. (1988). The hepatic encephalopathies. In (H.O. Conn, and J. Bircher, eds.) Hepatic Encephalopathy: Management with Lactulose and Related Carbohydrates. Medi-Ed Press, East Lansing, Michigan, pp. 3–14.Google Scholar
- Groeneweg M., Gyr K., Amrein R., Scollo-Lavizzari G., Williams R., Yoo J.Y., and Schalm, S. W. (1996). Effect of flumazenil on the electroencephalogram of patients with portosystemic encephalopathy. Results of a double blind, randomised, placebo-controlled multicentre trial. Electroencephalogr. Clin. Neurophysiol. 98:29–34.CrossRefPubMedGoogle Scholar
- Haefely W.E. (1990). The GABAA-benzodiazepine receptor: Biology and pharmacology. Neurobiol. Anx. 3:165–188.Google Scholar
- Meyer H.P., Legemate D.A., How K.L., van den Brom W.E., Voorhout G., Chamuleau R.A.F.M. et al. (1998). End-to-side portocaval anastomosis and partial hepatectomy in the dog as a model for chronic hepatic encephalopathy. J. Hepatol. 1998 (submitted)Google Scholar
- Roy S., Pomier Layrargues G., Butterworth R.F., and Huet P.M. (1988). Hepatic encephalopathy in cirrhotic and portacaval shunted dogs: Lack of changes in brain GABA uptake, brain GABA levels, brain glutamic acid decarboxylase activity and brain postsynaptic GABA receptors. Hepatology 8:845–849.PubMedGoogle Scholar